Afamelanotide Research Dosage: Published Protocol Reference
Afamelanotide dosage references vary by route and study context. The database lists Subcutaneous implant: 16 mg, Every 2 months (up to 3 implants per year for EPP). These are research-context references, not a universal protocol.
Direct Answer
Afamelanotide (Scenesse) is FDA-approved for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) - a rare, severely debilitating condition. The Phase 3 evidence in EPP is solid and the approval is well-founded. Outside EPP, evidence for vitiligo is emerging in Phase 2. This is a legitimate, approved therapeutic for its specific indication.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Skin & Beauty
- Best for
- Erythropoietic protoporphyria (EPP) phototoxicity prevention, vitiligo (investigational), melanocortin research
Research Dosage References
- <strong>Subcutaneous implant</strong> - 16 mg - Every 2 months (up to 3 implants per year for EPP) - FDA-approved dosing for EPP. Implant is inserted above the iliac crest. Slow release over approximately 10 days.
Half-Life
~30 minutes (peptide), but implant provides sustained release over ~10 days.
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Afamelanotide, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Regular skin and mole examinations recommended during treatment
- Not studied in patients with active melanoma or high melanoma risk
- Liver function should be monitored in EPP patients
- Use only for confirmed EPP diagnosis
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | EPP Phototoxicity Reduction (Level A), Skin Pigmentation (Level A), and Photoprotection (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Afamelanotide Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/melanotan-i-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.